Global Tissue Scaffolds Market 2018-2022
About Tissue Scaffolds
Tissue scaffolds are cell growth supporting structures composed of natural or synthetic biocompatible materials that provide a favorable environment for cell proliferation and differentiation.
Technavio’s analysts forecast the global tissue scaffolds market to grow at a CAGR of 12.14% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global tissue scaffolds market for 2018-2022. To calculate the market size, the report considers the revenue generated from the tissue scaffolds.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Tissue Scaffolds Market 2018-2022
Technavio recognizes the following companies as the key players in the global tissue scaffolds market: Bioventus, Integra Lifesciences, MiMedx Group, Organogenesis, RTI Surgical, and Smith & Nephew
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increasing technological advances. There is an increasing trend of technological advances in the global tissue scaffolds market. The introduction of 3D printing or additive manufacturing is increasingly being adopted for manufacturing scaffolds as it allows the researcher to control the size, shape, pore size, geometry, and mechanical properties of the scaffold. Additionally, the integration of computer-assisted design and modern medical imaging allows customized designing of scaffolds. There is also an increasing focus on the development of scaffolds containing nanomaterials as they can mimic the architecture of the normal extracellular matrix containing both nanofibers and microfibers.”
According to the report, one of the major drivers for this market is Growing occurrence of chronic and acute wounds. There is an increasing global prevalence of acute wounds such as surgical and traumatic wounds (abrasion, puncture, laceration, and incision) and chronic wounds such as venous ulcers, diabetic ulcers, and pressure ulcers. It is estimated that more than 250 million acute wounds are treated every year. It is estimated that 40-60 million traumatic wounds occur every year globally. In 2016, the global prevalence of surgical wounds was more than 135,000.
Further, the report states that one of the major factors hindering the growth of this market is Limitations of tissue scaffolds. The use of scaffolds in tissue engineering is associated with various limitations such as material associated infection, mechanical failure of materials, and immunogenic reactions to implanted materials. In 2013, Medtronic recalled 16,994 units of its INFUSE due to possible elevated endotoxin levels resulting from a process deviation. Furthermore, scaffolds derived from biologic tissues are more challenging to produce and can have issues related to quality control and lot-to-lot variability. The use of tissue scaffolds in clinical applications is still in its relatively early stage.
Bioventus, Integra Lifesciences, MiMedx Group, Organogenesis, RTI Surgical, and Smith & Nephew